MORRIS PLAINS, N.J., Aug. 27, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported financial results for the fourth quarter ended June 30, 2009, and for fiscal year 2009. The Company also highlighted recent key developments and planned activities for its clinical pipeline and Dock-and-Lock platform technology.
